Solving some of the world’s greatest health challenges
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.
Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.
Our core values hinge on the generation of robust clinical data that provide meaningful outcomes throughout the lives of our patients. Neurovalens technology aims to provide drug-free solutions to the worlds, greatest health epidemics.
Merging Neuroscience & Technology
Applications for Neurovalens Technology
Type 2 Diabetes / ObesityPrimary Target:
Central Melanocortin System (CMCS) & Arcuate Nucleus (Hypothalamus)Secondary Target:
Dorsal Motor Nucleus of Vagus & Nucleus of the Solitary Tract (Brainstem)
Our goal in type 2 diabetes is to improve glucose and insulin regulation and therefore positively influence HbA1c. Optimization of the central melanocortin system and regulation of the vagal nerve afferents are the primary target areas to allow better glycemic control and potentially reduce the need for pharmaceuticals. Poor regulation of metabolic homeostasis drives the development of obesity. Neurovalens targets key hypothalamic and brainstem nuclei involved in the neuro-regulation of body composition, with the aim of improving this dysregulation at source.
Suprachiasmatic Nucleus (SCN) (Hypothalamus)Secondary Target:
Intergeniculate Leaflet (IGL) (Thalamus)
Homeostatic centers within the hypothalamus and thalamus regulate the circadian rhythm the and sleep wake cycle. Neurovalens’ technology actively stimulates the SCN and IGL in a way that improves both sleep quality and duration.
Locus Coeruleus (LC) (Brainstem)Secondary Target:
Paraventricular Nucleus (PVN) (Hypothalamus)
Regulation of the parasympathetic and sympathetic pathways of the autonomic nervous system in response to stress can be influenced via the LC and the PVN. Connections to these centers via the medial vestibular nucleus allow both to be non-invasively targeted.
These are the start-ups that most impressed Britain’s top entrepreneurs and investors in 2019. There was a technology theme to the selections, while several on our panel of small business champions picked companies, they claimed were tackling some of the world’s biggest problems by treating Alzheimer’s disease and broadening access to education.
A BELFAST technology firm developing a number of specialised medical devices has received its second major cash injection in a month.
Neurovalens has been boosted by £750,000 from the Growth Finance Fund to support the launch of a new sleep product in the USA later this year.
Belfast-based health tech company Neurovalens is set to create 22 new jobs with the development of a ground-breaking medical device.
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings.